Last updated on May 2019

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry


Brief description of study

Post-marketing safety data on patients treated and untreated with eculizumab.

Detailed Study Description

The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.

Clinical Study Identifier: NCT01522183

Find a site near you

Start Over

Georgetown University Hospital

Washington, WA United States
  Connect »

Arthur James Cancer Hospital

Columbus, OH United States
  Connect »

Nepean Hospital

Penrith, Australia
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Austin Health

Heidelberg, Australia
  Connect »

Hopital Erasme

Brussels, Belgium
  Connect »

UZ Brussels

Brussels, Belgium
  Connect »

UZA (Adult)

Edegem, Belgium
  Connect »

CHU Ste Justine

Montréal, QC Canada
  Connect »

CHU Angers

Angers, France
  Connect »

CHG Bayonne

Bayonne, France
  Connect »

CHU Clermont Ferrand

Clermont-Ferrand, France
  Connect »

CHU Dijon

Dijon, France
  Connect »

CHU Grenoble

Grenoble, France
  Connect »

Le Kremlin Bicetre Hospital

Le Kremlin-Bicêtre, France
  Connect »

CHU de Montpellier

Montpellier, France
  Connect »

CH Perpignan

Perpignan, France
  Connect »

CHU Rangueil

Toulouse, France
  Connect »

CH Valenciennes

Valenciennes, France
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

CHU Ste Justine

Montréal, QC Canada
  Connect »

Le Kremlin Bicetre Hospital

Le Kremlin-Bicêtre, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.